Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.50 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522736 | 0.85 | MAPT (0.55) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3929351 | 0.82 | KDM4E (0.52) | KDM4EMAPTALDH1A1HPGDNPC1 | |
| SCHEMBL28561809 | 0.80 | KDM4E (0.49) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29156701 | 0.80 | KMT2A (0.50) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30744814 | 0.80 | KMT2A (0.50) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28360747 | 0.79 | KMT2A (0.48) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29156710 | 0.77 | SMN1; SMN2 (0.46) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29156672 | 0.77 | KMT2A (0.46) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29156673 | 0.76 | KMT2A (0.46) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30744897 | 0.76 | KMT2A (0.46) | KDM4ELMNASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9339527-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| CN-103145616-B | Nitrogen-containing heteroaryl compounds and the purposes in increase endogenous erythropoietin thereof | FIBROGEN INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-102977015-B | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin | FIBROGEN INC | 2015-05-06 | — | — | CN | disclosed |
| CN-102977016-B | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin | FIBROGEN INC | 2015-01-14 | — | — | CN | disclosed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | disclosed |
| CN-1816527-A | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin | FIBROGEN INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | KDM4E 1774/4885LMNA 2670/4885SMN1; SMN2 2209/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KDM4E 1817/4885LMNA 3562/4885SMN1; SMN2 2604/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KDM4E 1817/4885LMNA 3562/4885SMN1; SMN2 2604/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | KDM4E 1774/4885LMNA 2670/4885SMN1; SMN2 2209/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KDM4E 1817/4885LMNA 3562/4885SMN1; SMN2 2604/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | KDM4E 1774/4885LMNA 2670/4885SMN1; SMN2 2209/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | KDM4E 1814/4885LMNA 3635/4885SMN1; SMN2 2928/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | KDM4E 2455/4885LMNA 1542/4885SMN1; SMN2 527/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | KDM4E 1075/4885LMNA 2338/4885SMN1; SMN2 694/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | KDM4E 2395/4885LMNA 2349/4885SMN1; SMN2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.